NCT06092125Recruiting
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
Source: ClinicalTrials.gov · Last updated 16 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are: * Overcome the bottleneck of early accurate diagnosis and treatment in major brain diseases clinical practice. * Promote the clinical application of domestic PET/MR, enhance international competitiveness. Participants will have a PET/MR scan of the brain.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2300 (estimated)
- First submitted
- 9 Aug 2023
- Start date
- 1 Oct 2022
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Epilepsy, Alzheimer disease, Parkinson disease
- NCT number
- NCT06092125
What you commit to
- Study type: Observational
- Planned participants: 2300
- From 1 Oct 2022 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with poorly controlled blood sugar and ineffective medication intervention.
Other illness
- Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month.
- Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination.
Other
- Patients with absolute contraindications for PET/MR examination.
- Karnofsky Performance Score (KPS) \<60.
Who the study is looking for
- Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines.
- Patients admitted to our hospital for inpatient treatment.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.